Navigation Links
New genomic markers associated with risk of heart disease and early heart attack
Date:2/18/2009

Five short reports published simultaneously by the journal Nature Genetics have for the first time identified clusters of genetic markers associated with heart attack and coronary heart disease. In one of the reports, from the largest ever study of its kind, the Myocardial Infarction Genetics Consortium identified nine precise genes associated with an increased risk of infarction (MI), three of them newly discovered; the investigators said that these nine gene variants "identify 20% of the population at 2.25-fold increased risk for MI".

This study set out to find "single letter" differences in gene sequences (known as single nucleotide polymorphisms, SNPs) in 26,000 individuals in ten countries in order to explain why the pattern of early onset heart attack is often clustered in families. Using recently developed techniques for comparing an individual's gene sequences with reference sequences, the researchers found significant associations with risk of early heart attack for common SNPs in nine genetic regions.

One of the investigators, Dr Sekar Kathiresan from the Consortium, said: "Since we already have effective ways to reduce heart-attack risk, individuals at higher genetic risk may benefit from earlier intervention, something that needs to be tested in future studies."

Other studies reported in the journal included one from the Universite Pierre et Marie Curie in Paris which newly identified a new gene cluster (of three genes) as a possible susceptibility site for coronary artery disease. This study, unlike the first, compared individual and reference groups of SNPs (known as haplotypes).

Adding the studies together, the results suggest the identification of several new gene sites (loci) which appear to affect the risk of coronary heart disease and early heart attack. So far, the added risk from any abnormality in these gene sequences seems small, but the genomic association seems clear. Furthermore, there seems no specific theme to the SNPs involved, suggesting that, while the expression (phenotype) of heart disease and infarction may be consistent, the pathways of risk may be multiple at the genetic level.

Speaking on behalf of the European Society of Cardiology, Professor Thomas Lscher from the University of Zurich in Switzerland agreed that risk stratification via genetic pathways in coronary heart disease is an important future approach, but warned that these latest results reported in Nature Genetics were from case-control and not prospective studies. He said: "The next stage is to confirm the results in a prospective cohort to find out if they really do provide the same sort of prognostic information we already have from the classical risk factors."

Professor Lscher added that there is also a need to discover what the SNPs and gene clusters are doing biologically. "We have to find out what's going on at the cellular level as well," he said. "Several of the SNPs have been linked to cholesterol metabolism in the liver, but there are some new ones here associated with coronary artery disease and atherosclerosis.

"This is important work but we need further evidence with statistical power and biological plausibility."


'/>"/>

Contact: ESC Press Office
press@escardio.org
33-049-294-8627
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. NeoGenomics to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
2. Van Andel Research Institute of Michigan and Translational Genomics Research Institute of Arizona Undertake Unprecedented Alliance to Promote Science and Health
3. New genomic test can personalize breast cancer treatment
4. ANA and ISONG Co-Publish Genetics and Ethics in Health Care: New Questions in the Age of Genomic Health
5. Genomic Health to Announce Fourth Quarter and Year-End 2008 Financial Results and Host Conference Call on Tuesday, February 3, 2009
6. AutoGenomics CYP 2C19 Test Used in Study to Personalize Clopidogrel (Plavix) Dosing in Patients
7. Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and Commercialize DNA Methylation Cancer Tests
8. Genomic Health Announces Management Changes and New Responsibilities
9. Nutrigenomics - Developing Personalized Diets for Disease Prevention - Is the Focus of a Special Issue of OMICS
10. Genomic Health Announces Study Establishing the Utility of Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated with Aromatase Inhibitors
11. Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Achieve TMS West, ... opening a new office in San Clemente, California this month. Achieve TMS West ... California, successfully treating individuals struggling with major depression. Depression impacts over 15 million ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health is ... Health network on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, ... an exciting addition to our provider network, and the addition will benefit our ...
(Date:1/17/2017)... ... January 17, 2017 , ... SensorInsight ®, ... Sigfox in the U.S.A. to offer Internet of Things (IoT) solutions based ... large-scale environmental sensor deployments such as monitoring solutions used to detect potentially hazardous ...
(Date:1/17/2017)... ... January 17, 2017 , ... SC&H Group, a leading audit, tax, ... in its IT Advisory Services practice . Rossi is the third technology consulting ... for strategic IT guidance grows, and the practice continues to expand.     , Bringing more ...
(Date:1/17/2017)... ... 17, 2017 , ... Physicians Education Review®, LCC (PER®) announces ... for the 34th Annual Miami Breast Cancer Conference®, on March 9-12, 2017 at ... Talamo, said, “We are delighted to have Sandra Lee join us as our ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... YORK , Jan. 17, 2017 The ... 8.02 billion by 2021 from USD 6.35 billion in ... factors driving the growth of this market are rising ... demand for minimally invasive surgeries. The global ... procedure, application, and region. On the basis of type, ...
(Date:1/17/2017)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced ... Phase 3 clinical trial comparing the efficacy and safety ... prevention of hepatic veno-occlusive disease (VOD) in adult and ... are at high risk or at very high risk ... conducted across approximately 100 medical centers in ...
(Date:1/17/2017)... -- Market Research Future published a Half Cooked Research Report on Endoscopy ... USD 33.6 million during the period 2016 to 2022 from USD ... ... been examined as a swiftly growing market and expected to grow ... device in various regions.  The increasing growth in endoscopy procedures is ...
Breaking Medicine Technology: